All Posts

A new asset class is forming where healthspan meets property, drawing serious capital along with its own definitions and regulation. What the premium buys, what the research shows the building does, and how investors separate the projects funding the science from those borrowing its language.

The polite version of longevity is sleep, supplements and zone-two cardio. The frontier that actually moved capital this past year was stranger, and far more investable: cellular reprogramming reached its first patient, pharmaceutical capital moved into aging biology, and the field's harder questions, from embryo editing to the unregulated edge, came into the open. A clear-eyed look at how to tell a genuine breakthrough from an expensive one.

The startups leading the longevity capital flow in 2026, ranked. Altos Labs, Oura, Retro Biosciences and the new entrants reshaping longevity investment.

Family offices are no longer curious about longevity. They are building it. UBS projects an $8 trillion market by 2030 - surpassing AI. Here is where the conviction capital is going, who is leading the shift, and what the five capital patterns look like in practice.

From Brian Armstrong to Vitalik Buterin, founders who helped build the crypto economy are now investing in longevity science. The overlap reveals a deeper connection: both movements attempt to preserve value across time - financial and biological.

More than $5B in longevity and biotech capital was raised globally between July and November 2025. From reprogramming therapeutics to preventive clinics, the sector is entering a pivotal consolidation phase. Here’s what the new funding wave means for longevity’s future.

Where Longevity Is Growing Fastest (Geographical Trends) While certain countries consistently rank high for overall life expectancy, a...